CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10,228 enrolled
Drug / intervention
Pegylated interferon alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02106156
NCT02106156N/ACompleted
CompareCT.gov

Noninterventional Study on the Quality Assurance of the Therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa-2a (Pegasys®) and Ribavirin (e.g. Copegus®) With Main Focus Gastroenterologists - a Project in BNG (Association of German Resident Gastroenterologists), Part III

Hoffmann-La Roche·observational·Posted Apr 8, 2014·Updated Sep 23, 2016

In Brief

An observational study evaluating Pegylated interferon alfa-2a and Ribavirin for Chronic Hepatitis C. Completed, enrolled 10,228 participants across 1 site.

Detailed Summary

This observational study will examine the efficacy and safety of pegylated interferon (peginterferon) alfa-2a, mostly in combination with ribavirin treatment in chronic hepatitis C (CHC). Quality of care will also be assessed. Approximately 12% of the interferon-treated CHC patient population in Germany is expected to be studied over a period of 5 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 8, 2014
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 12.2 years ago

Interventions

Pegylated interferon alfa-2adrug

Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).

Ribavirindrug

Ribavirin administered according to corresponding summary of product characteristics (SmPC).